Clinical Effect of Autologous Bone Marrow Stem Cells in the Treatment of Lower Extremity Ischemic Diseases
The clinical effect of autologous bone marrow stem cells in the treatment of lower extremity ischemic diseases. All the patients in this study were 40 patients (45 limbs) with lower limb ischemic disease admitted to the vascular surgery department of our hospital from January 2018 to August 2019. The 40 patients in this study were divided into two groups: the control group of conventional treatment and the observation group of autologous bone marrow hematopoietic stem cell treatment, to compare the clinical treatment effect of the two groups. Before the treatment, there was no significant difference in the scores of pain, coolness and limp distance between the two groups (P > 0.05). After the treatment, the scores of data in the observation group were significantly lower than those in the control group, and the differences between the two groups were statistically significant (P < 0.05). Before the treatment, there was no significant difference between the two groups in ABI and TPO test results (P > 0.05). After the treatment, the data of the observation group was significantly better than that of the control group, and the difference between the two groups was statistically significant (P < 0.05). The clinical effect of autologous bone marrow stem cells in the treatment of lower extremity ischemic diseases is better, which can effectively guarantee the safety and safety of patients, and is worth promoting and using.